Octant Bio has embarked on a journey to demonstrate that the fusion of synthetic biology, chemistry and computational technologies may lead to new medicines for patients. That destination is still far away, but biotechnology is making progress and it has picked up something new for the journey.
Emeryville, Calif.-eighth Announce Wednesday obtain B round of financing of $ 80 million. The investment includes cash from Bristol-Myers Squibb, which has also signed on as a partner in the company’s drug research.
Octant, named after the marine navigation instrument, discovers drugs by engineering cell lines that biotech companies use to measure the biochemical activity of drug targets. The scientists then map those connections, showing the relationship of the chemicals to those drug targets. Computational techniques guide drug hunters through data to inform the design of small molecules that could be Octant’s drug candidates.
Octant co-founded by the Los Angeles professor of chemistry and biochemistry at the University of California, former CEO Sri Kosuri and Ramsey Homsany president was serving on Google and Dropbox.In a Thursday blog post, Kosuri and Homsany wrote that Octant reached a key milestone last year, showing that the company’s technology can generate small molecules capable of hitting multiple drug targets. They added that the molecules have shown efficacy in important disease areas, although they did not specify those areas.
With the fresh cash, Octant plans to expand the company’s technology platform and build out its drug pipeline. The study included rare diseases characterized by mutations that lead to a misstep — a protein that goes into the wrong place. Octant is using its technology to develop small molecule “chaperones” to correct mistrafficking. The drug research focuses on rare genetic diseases. BMS alliance focused on inflammation-related pathways. Neither was disclosed, nor was the research the goal of the league’s financial terms.
Eighth of a turn off $ 30 million A round of financing was launched in 2020. To date, the company said it has raised $ 115 million. B round of financing led by Catalio Capital Management. In addition to BMS, other participants in the current round of financing also includes early investors Andreessen Horowitz Bio Fund, Allen & Co. and 50 Years VC.
Photo by Flickr user fw190a8 Through knowledge sharing license
